Wednesday, July 8, 2026

Drug profile · INN

testolactone

testolactone (TESLAC) is a cytochrome p450 19a1 inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — testolactone
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

testolactone (TESLAC) is a cytochrome p450 19a1 inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN testolactone
Brand TESLAC
Mechanism Cytochrome P450 19A1 inhibitor
Target Aromatase
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Cytochrome P450 19A1 inhibitor

Primary target: Aromatase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. anastrozole Cytochrome P450 19A1 inhibitor
  2. exemestane Cytochrome P450 19A1 inhibitor
  3. letrozole Cytochrome P450 19A1 inhibitor

Frequently asked questions

What is testolactone?

testolactone (TESLAC) is a cytochrome p450 19a1 inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for testolactone?

TESLAC is a marketed brand name for testolactone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of testolactone?

testolactone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.